OBJECTIVES: To investigate potential differences in phenotype and behaviour of immature (iDC) and mature dendritic cells (mDC) from patients with RA and healthy subjects. METHODS: iDC and mDC were derived from blood monocytes of patients with RA and healthy controls following standardised protocols. FACS was used to analyse expression of FcgammaRI, II, and III and molecules to characterise DC. Discrimination between FcgammaRIIa and FcgammaRIIb was achieved by RT-PCR. Immunohistochemistry was performed on synovial biopsy specimens of three patients with RA and three healthy controls. TNFalpha production by iDC and mDC upon FcgammaR dependent stimulation was compared between patients with RA and controls by ELISA. RESULTS: iDC from patients with active RA but not from patients with inactive RA or healthy controls markedly up regulated FcgammaRII. mDC from patients with active RA also lacked the physiological down regulation of FcgammaRII that occurs upon maturation in both control groups. RT-PCR analysis confirmed the increased expression of FcgammaRII in RA-especially marked for FcgammaRIIb. FcgammaR dependent stimulation of DC using antigen-IgG immune complexes (IC) significantly increased TNFalpha production by DC from healthy subjects, but significantly decreased TNFalpha by DC from patients with RA. Overlapping expression patterns between FcgammaRII and DC-LAMP in the synovial tissue of patients with RA imply that in vivo, also, mature DC express increased levels of FcgammaRIIb. CONCLUSION: The presence and altered characteristics of DC during active RA suggest that DC help to modulate autoimmunity in RA. Further studies should elucidate the role of local factors in altering the function of DC in RA and in increasing expression of FcgammaRII.
OBJECTIVES: To investigate potential differences in phenotype and behaviour of immature (iDC) and mature dendritic cells (mDC) from patients with RA and healthy subjects. METHODS: iDC and mDC were derived from blood monocytes of patients with RA and healthy controls following standardised protocols. FACS was used to analyse expression of FcgammaRI, II, and III and molecules to characterise DC. Discrimination between FcgammaRIIa and FcgammaRIIb was achieved by RT-PCR. Immunohistochemistry was performed on synovial biopsy specimens of three patients with RA and three healthy controls. TNFalpha production by iDC and mDC upon FcgammaR dependent stimulation was compared between patients with RA and controls by ELISA. RESULTS: iDC from patients with active RA but not from patients with inactive RA or healthy controls markedly up regulated FcgammaRII. mDC from patients with active RA also lacked the physiological down regulation of FcgammaRII that occurs upon maturation in both control groups. RT-PCR analysis confirmed the increased expression of FcgammaRII in RA-especially marked for FcgammaRIIb. FcgammaR dependent stimulation of DC using antigen-IgG immune complexes (IC) significantly increased TNFalpha production by DC from healthy subjects, but significantly decreased TNFalpha by DC from patients with RA. Overlapping expression patterns between FcgammaRII and DC-LAMP in the synovial tissue of patients with RA imply that in vivo, also, mature DC express increased levels of FcgammaRIIb. CONCLUSION: The presence and altered characteristics of DC during active RA suggest that DC help to modulate autoimmunity in RA. Further studies should elucidate the role of local factors in altering the function of DC in RA and in increasing expression of FcgammaRII.
Authors: Hiroto Kita; Zhe-Xiong Lian; Judy Van de Water; Xiao-Song He; Shuji Matsumura; Marshall Kaplan; Velimir Luketic; Ross L Coppel; Aftab A Ansari; M Eric Gershwin Journal: J Exp Med Date: 2002-01-07 Impact factor: 14.307
Authors: T R D J Radstake; A W T van Lieshout; P L C M van Riel; W B van den Berg; G J Adema Journal: Ann Rheum Dis Date: 2005-05-05 Impact factor: 19.103
Authors: S Audia; K Santegoets; A G Laarhoven; G Vidarsson; O Facy; P Ortega-Deballon; M Samson; N Janikashvili; P Saas; B Bonnotte; T R Radstake Journal: Clin Exp Immunol Date: 2017-02-28 Impact factor: 4.330
Authors: T R D J Radstake; K C A M Nabbe; M H Wenink; M F Roelofs; A Oosterlaar; A W T van Lieshout; P Barrera; P L E M van Lent; W B van den Berg Journal: Ann Rheum Dis Date: 2005-05-05 Impact factor: 19.103
Authors: T R D J Radstake; R van der Voort; M ten Brummelhuis; M de Waal Malefijt; M Looman; C G Figdor; W B van den Berg; P Barrera; G J Adema Journal: Ann Rheum Dis Date: 2004-08-26 Impact factor: 19.103
Authors: A W T van Lieshout; P Barrera; R L Smeets; G J Pesman; P L C M van Riel; W B van den Berg; T R D J Radstake Journal: Ann Rheum Dis Date: 2004-07-15 Impact factor: 19.103
Authors: Dominika Swieboda; Erica L Johnson; Jacob Beaver; Lisa Haddad; Elizabeth Ann L Enninga; Matthew Hathcock; Sarah Cordes; Valerie Jean; Ivy Lane; Ioanna Skountzou; Rana Chakraborty Journal: J Immunol Date: 2020-03-25 Impact factor: 5.422